文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

单剂MGTA-145/普乐沙福高效动员HSC并在小鼠中实现地贫矫正

Single-dose MGTA-145/plerixafor leads to efficient mobilization and in vivo transduction of HSCs with thalassemia correction in mice.
PubMed 文献 · Blood Adv · 2021-01-01

研究在小鼠中测试2小时无G-CSF动员方案MGTA-145联合普乐沙福,用于体内HSC基因治疗。该方案动员HSC效果强,白细胞增多和IL-6升高较G-CSF+普乐沙福更轻。在地贫小鼠中经O6BG/BCNU体内选择后,>95%人γ-珠蛋白阳性红细胞且水平达小鼠β-珠蛋白36%,表型完全矫正。

要点

  • MGTA-145+普乐沙福2小时动员HSC,较G-CSF+普乐沙福白细胞增多和IL-6升高更轻。
  • 体内选择后>90%外周血单核细胞稳定GFP标记,载体随机多克隆整合。
  • 地贫小鼠中>95%人γ-珠蛋白阳性红细胞,水平达小鼠β-珠蛋白36%,表型完全矫正。

核心结论

  • 短时MGTA-145+普乐沙福动员可能适用于体内HSC基因治疗,包括地贫和镰状细胞病。

研究设计与样本

  • 小鼠研究,比较2小时无G-CSF的MGTA-145+普乐沙福与4天G-CSF+普乐沙福动员方案。
  • 采用IV注射HDAd5/35++载体系统进行体内HSC转导,并用地贫小鼠模型评估矫正效果。

主要发现

  • MGTA-145+普乐沙福组合可稳健动员HSC。
  • 与G-CSF+普乐沙福相比,MGTA-145+普乐沙福显著减少白细胞增多,且血清IL-6水平未升高。
  • 两种动员方案经O6BG/BCNU体内选择后,>90%外周血单核细胞实现稳定GFP标记。
  • 全基因组分析显示载体随机、多克隆整合。
  • 地贫小鼠中>95%人γ-珠蛋白阳性红细胞,水平达小鼠β-珠蛋白36%,表型完全矫正;二次受体中γ-珠蛋白标记比例和水平维持。

临床怎么用

  • MGTA-145+普乐沙福可作为体内HSC基因治疗的短时动员方案,避免G-CSF相关白细胞增多和IL-6升高。

局限性

  • 研究仅在小鼠中进行,尚未在人体验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We have developed an in vivo hemopoietic stem cell (HSC) gene therapy approach without the need for myelosuppressive conditioning and autologous HSC transplantation. It involves HSC mobilization and IV injection of a helper-dependent adenovirus HDAd5/35++ vector system. The current mobilization regimen consists of granulocyte colony-stimulating factor (G-CSF) injections over a 4-day period, followed by the administration of plerixafor/AMD3100. We tested a simpler, 2-hour, G-CSF-free mobilization regimen using truncated GRO-β (MGTA-145; a CXCR2 agonist) and plerixafor in the context of in vivo HSC transduction in mice. The MGTA-145+plerixafor combination resulted in robust mobilization of HSCs. Importantly, compared with G-CSF+plerixafor, MGTA-145+plerixafor led to significantly less leukocytosis and no elevation of serum interleukin-6 levels and was thus likely to be less toxic. With both mobilization regimens, after in vivo selection with O6-benzylguanine (O6BG)/BCNU, stable GFP marking was achieved in >90% of peripheral blood mononuclear cells. Genome-wide analysis showed random, multiclonal vector integration. In vivo HSC transduction after mobilization with MGTA-145+plerixafor in a mouse model for thalassemia resulted in >95% human γ-globin+ erythrocytes at a level of 36% of mouse β-globin. Phenotypic analyses showed a complete correction of thalassemia. The γ-globin marking percentage and level were maintained in secondary recipients, further demonstrating that MGTA145+plerixafor mobilizes long-term repopulating HSCs. Our study indicates that brief exposure to MGTA-145+plerixafor may be advantageous as a mobilization regimen for in vivo HSC gene therapy applications across diseases, including thalassemia and sickle cell disease.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Li C, Goncalves KA, Raskó T, et al. Single-dose MGTA-145/plerixafor leads to efficient mobilization and in vivo transduction of HSCs with thalassemia correction in mice. Blood Adv. 2021. PMID: 33646305. doi:10.1182/bloodadvances.2020003714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。